These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24698059)

  • 41. Companies look for profit in orphan drugs.
    Thompson CA
    Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
    [No Abstract]   [Full Text] [Related]  

  • 42. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 43. Promoting the development of drugs against rare diseases: what more should be done?
    Westermark K; Llinares J
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396
    [No Abstract]   [Full Text] [Related]  

  • 44. Duel over discounts. Pharma, providers at odds over 'orphan drugs'.
    Daly R
    Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763
    [No Abstract]   [Full Text] [Related]  

  • 45. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 46. Solutions to the R&D crisis for neglected diseases.
    Lancet; 2008 Nov; 372(9652):1784. PubMed ID: 19027471
    [No Abstract]   [Full Text] [Related]  

  • 47. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outrageous prices of orphan drugs: a call for collaboration.
    Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
    Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
    [No Abstract]   [Full Text] [Related]  

  • 50. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
    Kumar Kakkar A; Dahiya N
    Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Orphan drugs. Drugs for treatment of rare diseases].
    Hennemann A
    Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
    [No Abstract]   [Full Text] [Related]  

  • 52. Law and research could add up to profitable niche drugs.
    Haefner B
    Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
    [No Abstract]   [Full Text] [Related]  

  • 53. A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation.
    Pinxten W; Denier Y; Dooms M; Cassiman JJ; Dierickx K
    J Med Ethics; 2012 Mar; 38(3):148-53. PubMed ID: 21947805
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 56. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 58. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Medication: 15 years 'EU-directive orphan drugs'].
    Dooms M
    Bull Cercle Benelux Hist Pharm; 2015 Mar; (128):21-6. PubMed ID: 26137669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.